Daily Cardiology Research Analysis
Analyzed 169 papers and selected 3 impactful papers.
Summary
Three impactful cardiology papers span clinical trials, mechanistic genetics, and methodological innovation. Long-term follow-up of the FAME 2 trial shows fractional flow reserve-guided PCI provides durable benefit over medical therapy in stable CAD. A Science Advances study introduces an AI-enabled approach to reconstruct intracellular cardiac action potentials for multi-day monitoring, while a JACC Basic to Translational Science paper elucidates how an activating PRKG1 variant increases smooth muscle deformability, predisposing to aortopathy.
Research Themes
- FFR-guided revascularization and long-term outcomes in stable CAD
- AI-enabled electrophysiology for prolonged intracellular action potential monitoring
- Genetic and biomechanical mechanisms of inherited aortopathy (PRKG1)
Selected Articles
1. Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial.
In stable CAD with FFR ≤0.80 lesions, FFR-guided PCI demonstrated a durable reduction in the composite of death, MI, or urgent revascularization over a median 11.2 years, driven primarily by fewer urgent revascularizations. Mortality was similar, with a non-significant trend toward fewer MIs.
Impact: Provides definitive long-term randomized evidence supporting FFR-guided PCI over medical therapy in stable CAD, informing practice and guidelines.
Clinical Implications: For patients with FFR-positive lesions, revascularization guided by FFR offers sustained reduction in urgent revascularizations and composite events; shared decision-making should emphasize symptomatic status, ischemic burden, and patient values given neutral mortality.
Key Findings
- Median 11.2-year follow-up showed a win ratio of 1.25 favoring FFR-guided PCI for the composite endpoint.
- Large reduction in urgent revascularizations (win ratio 4.57) drove the composite benefit.
- All-cause mortality was similar (win ratio 0.88), and MI reduction trended in favor of PCI (win ratio 1.50, CI crossing 1).
Methodological Strengths
- Randomized design with long-term follow-up across 16 hospitals
- Hierarchical win-ratio analysis prioritizing mortality to address differential missingness
Limitations
- Composite benefit primarily driven by urgent revascularization rather than mortality
- Open-label nature and potential treatment crossover over long follow-up
Future Directions: Refine patient selection using physiology and imaging to identify subgroups with MI or mortality benefit; assess cost-effectiveness and quality-of-life over decades.
In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear. In the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 trial, patients with hemodynamically significant stenoses (fractional flow reserve (FFR) ≤ 0.80) were randomized to receive FFR-guided percutaneous coronary intervention (PCI) plus medical therapy (n = 447) or medical therapy alone (n = 441). At 5 years, FFR-guided PCI reduced the risk of the primary composite outcome of time to death, myocardial infarction or urgent revascularization, largely because of fewer urgent revascularizations. We now report the long-term clinical outcomes from this trial. Sixteen hospitals, contributing 748 randomized patients (161 women, 21.5%), participated in the long-term follow-up. The primary composite outcome was analyzed hierarchically using the unstratified win ratio, which addressed differential missingness of data on nonfatal outcomes in deceased patients by prioritizing comparisons on time to death. At a median follow-up of 11.2 years, the primary endpoint occurred in 150 of 447 patients (33.6%) in the PCI group versus 182 of 441 (41.3%) in the medical therapy group. PCI was superior in 29.2% of comparisons, medical therapy in 23.3%, and the two groups were tied in 47.5%, resulting in a win ratio of 1.25 in favor of PCI (95% confidence interval (CI) 1.01-1.56, P = 0.043). The corresponding win difference was 5.9% (95% CI 0.2-11.6), and the number needed to treat was 17 (95% CI 9-500). Win ratios were 0.88 for all-cause death (95% CI 0.66-1.17), 1.50 for myocardial infarction (95% CI 0.98-2.31) and 4.57 for urgent revascularization (95% CI 2.53-8.24). During long-term follow-up, FFR-guided PCI in patients with stable CAD and hemodynamically significant stenoses reduced the composite of death, myocardial infarction or urgent revascularization, primarily because of fewer urgent revascularizations. These long-term findings reaffirm the efficacy of FFR-guided PCI over medical therapy in patients with stable CAD. ClinicalTrials.gov registration: NCT06159231 .
2. Artificial intelligence-enabled "inherited noninvasive intracellular recording" for prolonged monitoring of cardiac action potentials.
An AI-MEA-EP pipeline enables multi-day reconstruction of intracellular cardiac action potentials from long-term extracellular recordings after a brief calibration via transient electroporation. The approach maintained high fidelity versus physically measured intracellular APs and captured pharmacologic and metabolic perturbation effects over >5 days.
Impact: Introduces a transformative, minimally invasive methodology to achieve prolonged intracellular electrophysiology, addressing a longstanding barrier in cardiac research and drug testing.
Clinical Implications: Not immediately clinical, but enables scalable, long-duration cardiomyocyte phenotyping for safety pharmacology and disease modeling, potentially improving translational fidelity of preclinical testing.
Key Findings
- AI (CNN-LSTM) with self-calibration converted long-term extracellular signals into intracellular APs with high consistency to physical intracellular recordings.
- Prolonged intracellular AP monitoring was demonstrated for >5 consecutive days under drug exposure and glucose challenge.
- Hybrid MEA-electroporation provided ~1-minute minimally invasive intracellular calibration without sustained membrane disruption.
Methodological Strengths
- Combines physical calibration with AI inference to ensure fidelity over multi-day recordings
- Validated against direct intracellular measurements and tested under pharmacologic/metabolic perturbations
Limitations
- In vitro cardiomyocyte system; generalizability to human tissues and in vivo contexts remains untested
- AI model performance may depend on initial calibration quality and drift management
Future Directions: Adapt to human iPSC-derived cardiomyocytes and multicellular tissues; standardize calibration protocols; evaluate integration in safety pharmacology pipelines and high-throughput screening.
Intracellular action potential (AP) recording that allows long-term monitoring is challenging because permanent membrane penetration is impossible due to cell death or resealing of perforated cell membrane. Herein, an "inherited noninvasive intracellular recording" methodology was proposed, which was based on the fusion of artificial intelligence (AI) with microelectrode array (MEA)-electroporation system (AI-MEA-EP) to enable prolonged monitoring of intracellular APs in cardiomyocytes. It used MEA-electroporation (MEA-EP) for minimally invasive collection of intracellular signals transiently (~1 minute), as well as noninvasive recording of extracellular signals in long term. The recorded extracellular APs were converted into corresponding intracellular APs by a convolutional neural network-long short-term memory-based AI model enhanced by model self-calibration. The intracellular APs detected by the AI-MEA-EP exhibited high consistency with those physically obtained through MEA-EP. It was demonstrated to monitor cardiac intracellular AP under drug treatments and glucose challenging during >5 consecutive days. This method offers a unique solution to achieve prolonged recording of intracellular signals for advancing cardiac research.
3. Activating PRKG1 Variant Enhances Smooth Muscle Cell Deformability To Cause Aortopathy.
An activating PRKG1 (V219I) variant increases smooth muscle cell size, deformability, and cytoskeletal/ECM signaling abnormalities, weakening structural integrity and shifting tissue mechanics toward greater elasticity. This provides a mechanistic model for genetic predisposition to aortic dissection even when aortic diameters are near-normal.
Impact: Links a specific activating PRKG1 variant to quantifiable biomechanical and cytoskeletal phenotypes in vascular smooth muscle, advancing pathogenesis understanding of inherited aortopathy.
Clinical Implications: Suggests that carriers of activating PRKG1 variants may be at risk of dissection despite minimally enlarged aortas; supports earlier surveillance, family screening, and consideration of biomechanical markers beyond diameter.
Key Findings
- PRKG1 V219I-expressing vascular smooth muscle cells were larger and more deformable with aberrant actin cytoskeleton dynamics.
- Altered extracellular matrix signaling and weakened structural integrity suggested a shift toward increased tissue elasticity.
- Provides a mechanistic model explaining predisposition to aortic dissection independent of pronounced aortic dilation.
Methodological Strengths
- Multimodal cellular phenotyping integrating deformability and cytoskeletal dynamics
- Mechanistic linkage between genotype and biomechanical properties of smooth muscle
Limitations
- Focused on a single variant; generalizability across PRKG1 mutations requires study
- Predominantly in vitro cellular assays without prospective clinical outcome validation
Future Directions: Evaluate in vivo vascular biomechanics in variant carriers, develop imaging/biomarker surrogates of tissue elasticity, and assess surveillance thresholds beyond diameter.
Aortic dissection can strike without warning. Whereas the condition is typically linked to aging and chronic hypertension, rare genetic variants emerge as silent culprits. One variant, V219I in PRKG1, has been found in patients with aortic aneurysms despite near-normal aortic diameters. Vascular smooth muscle cells expressing the V219I variant were larger, more deformable, and showed aberrant actin cytoskeleton dynamics. They exhibited altered extracellular matrix signaling and weakened structural integrity, highlighting a shift toward increased tissue elasticity as the causal molecular pathomechanism. These findings offer a mechanistic model for how PRKG1 variants predispose to aortic dissection.